Navigation Links
Chemokine Therapeutics Announces Preliminary Results of CTCE-9908,Phase Ib/II Clinical Trial in Late Stage Cancer Patients

TSX: CTI OTCBB: CHKT

VANCOUVER, March 12, 2007 /PRNewswire-FirstCall/ - Chemokine Therapeutics Corp. ("Chemokine Therapeutics" or the "Company") , a biotechnology company developing chemokine-based therapies to treat cancer, blood disorders, and vascular disease today announced positive preliminary data and the successful completion of the dose-escalation portion of its Phase Ib/II clinical trial for CTCE-9908, the Company's anti-cancer drug candidate. No dose limiting toxicities were observed in any of the cancer patients and two out of three patients with ovarian cancer responded positively and exhibited stable disease.

Chemokine Therapeutics will now proceed with the remaining portion of the clinical trial in which up to twenty additional patients will be treated at 5mg/kg/day. The Company expects to enroll the remainder of the patients and complete the current trial by the end of Q3 2007. The Company has also accelerated its efforts to initiate a large Phase II program in the U.S. by the end of 2007. Accordingly, a pre-IND meeting has been scheduled with the FDA to discuss the Company's future clinical trial program.

"We are very pleased that no dose-limiting toxicities were observed in the first part of the trial and encouraged by the positive outcome in the small group of ovarian cancer patients," said Dr. Hassan Salari, Chemokine Therapeutics President and CEO. "It is quite remarkable to see clinical evidence of efficacy considering these patients have exhausted every therapeutic avenue. We are now looking to rapidly expand the number of patients in Phase II clinical trials of CTCE-9908 to examine the potential broader applicability of this novel oncology drug in the treatment of cancer patients."

The primary purpose of this study is dose-selection and evaluation of safety and tolerability of CTCE-9908. CTCE-9908 is administered via a 30-minute infusion on weekdays over a treatment p
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
4. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
5. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
6. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
7. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
8. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
9. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
10. Trophos Publishes ALS Article in Journal of Pharmacology and Experimental Therapeutics
11. Novelos Therapeutics Announces Encouraging Results in Ongoing Phase 2 Ovarian Cancer Trial at Dana-Farber/Partners Cancer Care
Post Your Comments:
(Date:9/19/2014)... 19, 2014 /PRNewswire-iReach/ -- "United States ... provides key market data on the ... The report provides value, in millions ... units) within market categories – Bronchoscopes, ... & Gastroscopes, Duodenoscopes, Laparoscopes, Hysteroscopes, Sinuscopes, ...
(Date:9/19/2014)... -- Kiromic, LLC, a Lubbock bio-pharmaceutical ... the former chancellor of Texas Tech University, to its board ... 2014, after raising $1.2 billion for the university. ... the most successful chancellor in the history of Texas Tech ... investor, but also as our new vice chairman of the ...
(Date:9/19/2014)... 19, 2014 According to ... (Cryotherapy, Heat, therapy, Hydrotherapy), Accessories (Posture Mirror, Exercise Ball), ... technologies - Global Forecast to 2019" published by ... reach $19,786.3 Million by 2019 from $14,240.0 Million ... 2014 to 2019. Browse 74 market ...
Breaking Medicine Technology:United States General Surgery Devices Market to 2020 - Endoscopy, Bariatric Surgery, Aesthetic Lasers and Energy, Biopsy Devices, Hernia Repair, Non-Vascular Stents 2United States General Surgery Devices Market to 2020 - Endoscopy, Bariatric Surgery, Aesthetic Lasers and Energy, Biopsy Devices, Hernia Repair, Non-Vascular Stents 3United States General Surgery Devices Market to 2020 - Endoscopy, Bariatric Surgery, Aesthetic Lasers and Energy, Biopsy Devices, Hernia Repair, Non-Vascular Stents 4United States General Surgery Devices Market to 2020 - Endoscopy, Bariatric Surgery, Aesthetic Lasers and Energy, Biopsy Devices, Hernia Repair, Non-Vascular Stents 5Former Texas Tech Chancellor Named New Vice Chairman of the Board of Kiromic, LLC 2Physiotherapy Equipment Market Worth $19,786.3 Million by 2019 2Physiotherapy Equipment Market Worth $19,786.3 Million by 2019 3Physiotherapy Equipment Market Worth $19,786.3 Million by 2019 4
... can be very serious for everybody. So serious, in fact, ... that nearly everyone get a flu vaccine. This is particularly ... people age, it becomes more difficult for them to fight ... of serious flu-related complications, including pneumonia, hospitalization and even death. ...
... Caremark Corporation (NYSE: CVS ) will be ... at 8:30 a.m. (ET) with analysts and investors to ... as its initial guidance for 2011. (Logo: ... call will be broadcast simultaneously through the Investor Relations ...
Cached Medicine Technology:Anthem Blue Cross and Blue Shield in Nevada Urges Seniors to Get Flu, Pneumonia Vaccines 2Anthem Blue Cross and Blue Shield in Nevada Urges Seniors to Get Flu, Pneumonia Vaccines 3Anthem Blue Cross and Blue Shield in Nevada Urges Seniors to Get Flu, Pneumonia Vaccines 4
(Date:9/22/2014)... In CHAMPS Patient Experience's most recent blog post, ... Meeting , Toya Gorley shares her thoughts on the ... Leader’s Board meeting this summer, which was comprised of ... to be exhilarating! Many topics were discussed, including:, ... the patient experience , Technology solutions ...
(Date:9/22/2014)... well-known wedding dress manufacturer and retailer, has recently announced a ... In addition, the company has also deiced to launch a ... in the new range is now provided with a deeply ... has thousands of unique special occasion outfits for sale; almost ... Its products are brand new and made with soft materials. ...
(Date:9/21/2014)... smoke, those using e-cigarettes (in addition to traditional cigarettes) ... to have quit smoking traditional cigarettes than non-users. Published ... of the American Cancer Society, the findings raise doubts ... patients give up smoking. , Because of the risks ... be advised to quit. But the rising use of ...
(Date:9/21/2014)... Phoenix, AZ (PRWEB) September 21, 2014 ... in Phoenix Arizona announces record demand for aggressively discounted ... of accidents occurring throughout the Valley each year, it ... to have access to discounted attorney’s fees as a ... said, Hastings and Hastings has been a frontrunner when ...
(Date:9/21/2014)... likely to trigger an allergy to peanuts than raw ... The researchers say that specific chemical changes caused by ... recognised by the body,s immune system, ,priming, the body ... time it sees any peanuts. , The results might ... peanut allergies in the Western world compared to populations ...
Breaking Medicine News(10 mins):Health News:CHAMPS' Toya Gorley Discusses the Thought-Provoking Conversation at The Leader’s Board Summer Meeting 2Health News:Discounted Plus Size Wedding Dresses Available At Fancyflyingfox.com 2Health News:E-cigarettes unhelpful in smoking cessation among cancer patients 2Health News:Hastings & Hastings Announces Record Demand For Aggressively Discounted Accident Victim Attorney’s Fees 2Health News:Hastings & Hastings Announces Record Demand For Aggressively Discounted Accident Victim Attorney’s Fees 3Health News:Dry roasting could help trigger peanut allergy 2
... Rochester study helps to explain why men get liver cancer more ... pathway, by showing a direct link between the androgen receptor, which ... it relates to the deadly cancer. The study is published ... journal from the American Association for the Advancement of Science, AAAS. ...
... ... , ... today unveiled a men,s line of wallets2wear, the revolutionary new line of wearable wallets. These ... carry a man,s credit card, ID, cash and key. They are convenient, clever and comfortable., , ...
... ... out why. This sweepstakes takes the winner and three guests to the beautiful Bay Of ... trip for four for bloggers who enter the kiwi a-go-go contest. No purchase necessary. ... (PRWEB) May 20, 2010 -- ...
... have received a $3.3 million National Institutes of Health ... and language development in bilingual children who speak English ... with those who have no delays. "Spanish speakers ... and make up 79 percent of the school age ...
... ... addresses the rise of ADHD based on scientific evidence, including toxins such as pesticides, ... public , ... May 19, 2010 -- A new book on ADHD by Dr. Sanford Newmark, one ...
... likely to develop problem , WEDNESDAY, May 19 (HealthDay ... other similar medications, may prompt long-term hearing loss among ... 18 issue of the Archives of Otolaryngology -- ... of Alabama at Birmingham discuss evidence supporting an association ...
Cached Medicine News:Health News:Androgen receptor may explain male dominance in liver cancer 2Health News:Androgen receptor may explain male dominance in liver cancer 3Health News:Androgen receptor may explain male dominance in liver cancer 4Health News:Wallets2wear Now Available for Men 2Health News:Win A Trip To New Zealand For Four: The Great Kiwi Adventure and ZESPRI's Kiwi A-Go-Go Bloggers' Contest 2Health News:Researchers get $3.3 million grant to investigate language outcomes of bilingual children 2Health News:Book Delivers Latest ADHD Research, Treatments & Results 2Health News:Book Delivers Latest ADHD Research, Treatments & Results 3Health News:Viagra Linked to Hearing Loss 2
Anti-Skin Antibody (ASA) Test Kit: Pemphigus and Bullous Pemphigoid...
... Medical Professional Diagnostics is a leading provider ... and DFA test menu that includes kits ... as well as miscellaneous conjugates and components. ... a wide assortment of substrates and kit ...
... technologies and designs, the Digital ClearMag ... of the posterior pole. Using this ... previously unattainable with the binocular indirect ... and comprehensive views, helping to reduce ...
... Our ELISA products for autoimmune testing ... ELISAs, as well as specific reflex tests ... Sm, Sm/RNP, SS-A (Ro), SS-B (La), Scl-70 ... family includes a full line of products ...
Medicine Products: